Appointments and advancements for May 5, 2026

Endpoints NewsJ&J's IBD combo fails Phase 2 studies, but will move into pivotal testing

FierceBiotechPfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager

FierceBiotechSanofi expands AI capabilities, investing $294M to scale Toronto hub

Endpoints NewsMadrigal extends MASH deal streak with Arrowhead drug that J&J didn't want

Endpoints NewsHealthcare organizations are increasingly building their own AI tools

PharmaVoiceWhat’s at stake in Amgen’s showdown with the FDA?

Promega BlogBeyond the Liver: How Liposomal LNPs Are Expanding the Reach of mRNA Delivery

BioPharma DiveVertex earnings get muted investor response

BioPharma DiveCytokinetics heart drug scores in closely watched trial

FierceBiotechViridian’s Tepezza rival racks up second phase 3 win, clearing path to FDA

BioWorldAppointments and advancements for May 5, 2026

BioWorldFinancings for May 5, 2026